Processa Pharmaceuticals, INC Form 4 insider transactions

Geraldine Pannu, a Director at Processa Pharmaceuticals, Inc., was granted 175,299 shares of restricted stock, with a portion contingent on stockholder approval of a revised incentive plan.

Processa Pharmaceuticals, Inc. Director Justin W. Yorke was granted 175,299 shares of restricted stock, with a portion contingent on stockholder approval and vesting by mid-2026.

Patrick Lin, Chief Business Strategy Officer of Processa Pharmaceuticals, reports the acquisition and disposal of common stock on April 1, 2025.

Wendy Guy, Chief Administrative Officer of Processa Pharmaceuticals, reports the acquisition of 14,482 shares of common stock on April 1, 2025, through the distribution of vested restricted shares.

Sian Bigora, Chief Development Officer of Processa Pharmaceuticals, reports the acquisition and disposal of common stock, including a distribution of vested restricted shares.

David Young, President of Research & Development at Processa Pharmaceuticals, reports transactions involving common stock, including acquisition and disposal of shares.

Justin W. Yorke, a director of Processa Pharmaceuticals, filed an amendment to a previous Form 4, detailing warrant acquisitions and holdings through indirect ownership.

David Young, President of Research & Development at Processa Pharmaceuticals, files an amendment to a previous Form 4, detailing changes in his beneficial ownership of company stock and warrants.

Patrick Lin, Chief Business Strategy Officer of Processa Pharmaceuticals, reports acquisition of shares and warrants, both directly and indirectly through the Lin Family Trust.

George Ng, CEO of Processa Pharmaceuticals, files an amendment to a previous Form 4, clarifying the beneficial ownership of common stock and warrants held indirectly through a trust and an IRA.

Justin W. Yorke, a director at Processa Pharmaceuticals, purchased 12,400 shares of common stock at a price of $0.7975 per share.

Processa Pharmaceuticals CEO George Ng reports the acquisition of 87,200 shares of common stock at $0.7975 per share on January 27, 2025.

David Young, President of Research & Development at Processa Pharmaceuticals, recently acquired 124,500 shares of common stock at a price of $0.7975 per share.

Patrick Lin, Chief Business Strategy Officer of Processa Pharmaceuticals, recently acquired 43,500 shares of common stock at a price of $0.7975 per share.

Justin W. Yorke, a director of Processa Pharmaceuticals, acquired 31,206 shares of restricted stock on September 3, 2024.

Director Geraldine Pannu reports acquisition of 31,206 shares of Processa Pharmaceuticals restricted stock on September 3, 2024.

Director James R. Neal acquired 31,206 shares of restricted stock in Processa Pharmaceuticals, Inc. on September 3, 2024.

Khoso Baluch, a director of Processa Pharmaceuticals, acquired 31,206 shares of restricted stock on September 3, 2024.

Sian Bigora, Chief Development Officer of Processa Pharmaceuticals, reports multiple transactions involving common stock and restricted stock units.

James H. Stanker, CFO of Processa Pharmaceuticals, reports transactions involving common stock and restricted stock units.

Patrick Lin, Chief Business Strategy Officer of Processa Pharmaceuticals, reports transactions involving common stock and restricted stock units.

Wendy Guy, Chief Administrative Officer of Processa Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units.

David Young, President of Research & Development at Processa Pharmaceuticals, reports transactions involving common stock and restricted stock units.

Russell Skibsted, CFO of Processa Pharmaceuticals, reports the acquisition of 28,000 restricted stock units.

David Young, President of Research & Development at Processa Pharmaceuticals, reports transactions involving common stock and restricted stock units after a 20-for-1 reverse stock split.

James H. Stanker, CFO of Processa Pharmaceuticals, reports the distribution of vested restricted shares and tax withholding following a 20-to-1 reverse stock split.

Patrick Lin, Chief Business Strategy Officer of Processa Pharmaceuticals, reports stock transactions including the distribution of vested restricted shares and adjustments due to a 20-to-1 reverse stock split.

Sian Bigora, Chief Development Officer of Processa Pharmaceuticals, reports transactions involving common stock and restricted stock units, adjusted for a recent 20-to-1 reverse stock split.

Wendy Guy, Chief Administrative Officer of Processa Pharmaceuticals, reports the vesting and distribution of restricted stock units and subsequent adjustments due to a reverse stock split.